Objective: Metabolically healthy individuals are known to be resistant to cardiovascular disease development. However, a considerable fraction of those individuals shows deteriorated metabolic health over time. Although skeletal muscle is the primary insulin-responsive target organ, a longitudinal investigation of the skeletal muscle mass in relation to the development of metabolically unhealthy phenotype has not been performed. We aimed to evaluate whether greater skeletal muscle mass is an independent protective factor for the development of metabolically unhealthy phenotype. 
| INTRODUC TI ON
Obesity is a major health problem and an important risk factor for cardiovascular disease (CVD), type 2 diabetes mellitus (DM) and several types of cancer.
1 However, not all individuals with obesity are at high risk of metabolic morbidity and a subgroup of individuals appears resistant to the development of metabolic and CVDs. 2 This condition has been characterized as "metabolically healthy obesity (MHO)," and MHO individuals have a favourable body composition, lipid profile, inflammatory status and adipokine levels. 2 Similarly, despite their normal body mass index (BMI), there is a subgroup of nonobese individuals who have abnormal metabolic parameters, which result in cardiometabolic diseases, and those subjects were characterized as "metabolically unhealthy nonobese subjects (MUNO)."
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Although individuals with metabolically healthy phenotype have lower CVD risk than those with unhealthy phenotype, 2,3 recent longitudinal studies suggested that healthy phenotype is an unstable condition, because metabolic parameters may change over time.
Indeed, approximately 30%-50% of MHO individuals became unhealthy phenotype during follow-up periods. [4] [5] [6] Because maintaining healthy phenotype has been important to delay CVD, 7 research has focused on identifying parameters that may predict metabolic deterioration to unhealthy phenotype. Previous studies suggested that high waist circumference (WC), greater visceral abdominal fat, hypertension, glucose dysregulation, low levels of high-density lipoprotein cholesterol (HDL-C), hypertriglyceridemia and high levels of homeostasis model assessment of insulin resistance (HOMA-IR)
independently predict development of unhealthy phenotype. [5] [6] [7] [8] [9] Among those factors, insulin resistance was considered the main mechanism that predicted metabolic deterioration to unhealthy phenotype. 5, 9 Because skeletal muscle is the primary insulin-responsive target organ, low skeletal muscle mass reduces insulin-mediated glucose disposal and promotes insulin resistance, which may result in metabolic deterioration to unhealthy phenotype. 10, 11 Consistent with these findings, a few cross-sectional studies have shown that low skeletal muscle mass was associated with metabolically unhealthy phenotype. 10, 11 However, longitudinal studies investigating the association between muscle mass and the development of metabolically unhealthy phenotype were scarce, and it is not known whether increased muscle mass can prevent future metabolic deterioration.
Thus, we aimed to evaluate whether greater skeletal muscle mass is an independent protective factor for future development of metabolically unhealthy phenotype. We enrolled a large number of metabolically healthy individuals at baseline and followed this cohort for 4 years.
| MATERIAL S AND ME THODS

| Study population
We conducted a retrospective cohort study based on individuals aged ≥30 years, who underwent a routine health evaluation at the Asan Medical Center (AMC, Seoul, Republic of Korea) in 2012 (baseline) and a follow-up examination in 2016 (n = 16 917, Figure 1 ). Each participant completed a questionnaire on previous diseases, medication, exercise, alcohol intake and smoking habits. History of CVD was defined as physician-diagnosed myocardial infarction, congestive heart failure and/or cerebrovascular accidents. Diabetes was defined as fasting plasma glucose (FPG) levels ≥7.0 mmol/L or glycated haemoglobin (HbA1c) levels ≥6.5%. 12 In addition, individuals taking anti-diabetic medication were considered to have diabetes.
F I G U R E 1 Flow diagram of study subjects Hypertension was defined as systolic and/or diastolic blood pressure (BP) ≥140/90 mm Hg and/or taking antihypertensive medication. Regular aerobic exercise was defined as engaging in moderate intensity aerobic activity for 30 minutes, 5 days/wk minimum or vigorous-intensity aerobic activity for 20 minutes, 3 days/wk minimum. 13 Regular resistance exercise was defined as engaging in resistance training sessions 3 days/wk minimum. 14 Smoking status was categorized as noncurrent or current. Beverage-specific alcohol consumption was calculated in g/day on the basis of the alcohol content, the frequency of drinking and the amount consumed. 15 Menopausal status was classified as premenopausal, postmenopausal or surgical menopausal status (menopause induced by hysterectomy with/ without oophorectomy).
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We excluded individuals who met the following criteria ( Figure 1 
| Laboratory measurements
After overnight fasting, early morning venous blood samples were collected and analysed by a central, certified laboratory at the AMC.
Fasting total cholesterol, HDL-C, low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), uric acid, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were measured with enzymatic colorimetric methods using a Toshiba 200FR Neo analyser (Toshiba Medical System Co., Ltd., Tokyo, Japan). Gamma-glutamyltransferase (GGT) levels were measured using the l-γ-glutamyl-pnitroanilide method (Toshiba). Serum bilirubin concentrations were determined with the vanadate oxidation method using a Toshiba
200FR Neo Chemistry autoanalyser (Toshiba Medical Systems
Corp.). Creatinine levels were measured using the Jaffe method, and eGFR was calculated using the Modification of Diet in Renal Disease study Equation.
19 Serum thyroid-stimulating hormone (TSH) and FT4 levels were measured using the TSH-CTK-3 immunoradiometric assay kit (DiaSorinS.p.A, Saluggia, Italy) and FT4 RIA kit (Beckman Coulter/Immunotech, Prague, Czech Republic), respectively. Highsensitivity C-reactive protein (hsCRP) and FPG levels were measured using the immunoturbidimetric method (Toshiba) and the enzymatic colorimetric method using a Toshiba 200 FR autoanalyser (Toshiba).
Serum insulin concentrations were determined with an immunoradiometric assay (TFB, Tokyo, Japan). Ion-exchange high-performance liquid chromatography (Bio-Rad Laboratories, Inc, Hercules, CA, USA) was used to measure HbA1c levels. HOMA-IR was calculated as the product of fasting serum insulin (μU/mL) and FPG (mmol/L) levels divided by 22.5. All enzymatic activities were measured at 37°C. 
| Anthropometric and body composition measurements
| Statistical analysis
To test whether the effect of ASM/weight on metabolic deterioration differed according to sex or obesity status, we performed interaction analysis. Significant interaction effects were found between sex and ASM/weight and obesity status and ASM/weight (all P < 0.001). Thus, statistical analyses were performed separately by TA B L E 1 Baseline characteristics of nonobese men and women that remained metabolically healthy or progressed to unhealthy phenotype 
| RE SULTS
| Baseline clinical characteristics of study participants
At baseline, the mean age of the 9033 participants was 49.9 ± 7.9 years and mean BMI was 22. 
TA B L E 1 (Continued)
TA B L E 2 Baseline characteristics of men and women with obesity that remained metabolically healthy or progressed to unhealthy phenotype progressed to unhealthy phenotype included more postmenopausal women at baseline compared with women that remained metabolically healthy. Nonobese men and women that progressed to unhealthy phenotype showed higher BMI, WC, body fat mass, body fat percentage at baseline, but lower ASM/weight than those that did not.
Similar analysis was performed for obese subjects (Table 2) .
MHO subjects that progressed to MUO showed unfavourable metabolic parameters, higher BMI and WC at baseline. Obese men that developed unhealthy phenotype showed higher body fat mass, body fat percentage and lower ASM/weight compared with those that remained healthy phenotype. These associations were not observed in obese women.
| Risk factors for predicting progression towards metabolically unhealthy phenotype
To determine which variables independently predicted future conversion to metabolically unhealthy phenotype, a multiple logistic regression model was applied (Table 3 ). The category that remained metabolically healthy in each subgroup served as the reference. Only in nonobese women, hsCRP was significantly associated with increased risk of progression. In all groups except females with obesity, whole-body fat per cent was significantly correlated with risk of progression, whereas baseline ASM/weight was inversely correlated with risk of progression after adjustment.
| Progression to metabolically unhealthy phenotype according to ASM/weight quartiles
To assess the independent role of skeletal muscle mass in preventing the future conversion to unhealthy phenotype, we calculated sexand obesity-specific cut-off points for ASM/weight quartiles and further classified participants using these values (Tables 4, and 5 ). In nonobese men and women, high ASM/weight at baseline was significantly associated with decreased risk of progression to metabolically unhealthy phenotype in unadjusted and adjusted models (Table 4) . We applied the same multiple logistic regression model for men and women with obesity ( 
0.336
Values are mean (SD), median (interquartile ranges) or number (%). ALT, alanine aminotransferase; ASM, appendicular skeletal muscle mass; AST, aspartate aminotransferase; BMI, body mass index; BP, blood pressure; FPG, fasting plasma glucose; GGT, gamma-glutamyltransferase; HbA1c, haemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; 25(OH)D, 25-hydroxyvitamin-D; LDL-C, low-density lipoprotein cholesterol; WC, waist circumference; TG, triglyceride.
TA B L E 2 (Continued)
was attenuated and was not significant after further adjustment for clinical variables in models 2-4. For obese women, no significant associations between ASM/weight quartiles and conversion to unhealthy phenotype were observed.
We performed additional analyses using a stricter definition of metabolically unhealthy phenotype (≥1 metabolic risk factor according to Wildman criteria) and applied the same multiple logistic regression analysis (Supporting Information Tables S1 and S2 ). In nonobese men, the ORs for the progression to unhealthy phenotype were significantly lower in the higher skeletal muscle mass group (Q4) than the lower muscle mass group (Q1) in unadjusted and various adjusted models (Supporting Information Table S1 ). In nonobese women, similar patterns were observed in the unadjusted model and models 1 and 2, but the association was not significant in models 3 and 4. In obese men and women, no significant associations were observed (Table S2 ).
| D ISCUSS I ON
In this study, approximately one-fourth (23.3%) of nonobese and half (49.5%) of obese subjects deteriorated to the unhealthy phenotype during a 4-year follow-up period. We found that greater skeletal muscle mass at baseline was significantly associated with a decreased risk of progression to metabolically unhealthy phenotype in nonobese individuals, but not in individuals with obesity after adjustment.
Obesity is a major risk factor for metabolic syndrome and CVD. However, there is huge variability between individuals regarding the risk of obesity-related morbidity and metabolic risk factors are more important for future disease burden than body weight itself. 2 To segregate individuals that may be relatively resistant to future CVD, various detailed criteria were applied to define MHO and MHNO.
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Although metabolically healthy individuals exhibited higher insulin sensitivity and had a favourable metabolic profile at baseline, a considerable fraction of them showed deteriorated metabolic health over time. [4] [5] [6] In contrast, individuals that maintained their metabolic health were not at increased risk for development of diabetes and CVD. 4 Thus, identifying clinical risk factors associated with metabolic deterioration and sustaining a metabolically benign status may be useful to lower CVD risk. 7 Previous studies suggested that high WC, greater visceral abdominal fat, hypertension, glucose dysregulation, low HDL-C, hypertriglyceridemia and high HOMA-IR levels were independent predictors of unhealthy phenotype development. 5, [7] [8] [9] Of these factors, insulin resistance was regarded as the primary underlying mechanism that predicts metabolic deterioration to unhealthy phenotype. 5 As an important determinant of insulin resistance, it has been reported that the distribution of fat, especially visceral fat, was independently associated with the development of metabolically unhealthy phenotype. 8 Although skeletal muscle is another major body composition factor determining insulin resistance, only a few cross-sectional studies reported that low skeletal muscle mass TA B L E 3 Odds ratios (ORs) with 95% confidence intervals (CI) from logistic regression model predicting conversion to metabolic unhealthy phenotype after adjusting for confounding factors a was associated with metabolically unhealthy phenotype, 10,11 and longitudinal studies were scarce. Thus, it was unclear whether low skeletal muscle mass causes metabolically unhealthy phenotype or whether elements associated with unhealthy phenotype, such as low-grade inflammation, insulin resistance and oxidative stress, were responsible for decreased muscle mass. 10, 11 In our retrospective cohort study, in nonobese individuals, greater skeletal muscle mass at baseline was strongly associated with a decreased risk of progression to unhealthy phenotype even after adjusting for various metabolic variables, including BMI and WC, implying that skeletal muscle mass may play an important protective role against future metabolic deterioration.
In our analysis, greater skeletal muscle mass significantly reduced the risk of metabolic deterioration in nonobese, but not obese individuals after adjustment (Tables 4, and 5) . Although a relatively smaller number of the obese subgroup compared with nonobese subgroup might result in clinical insignificance, the harmful effects of excess fat in individuals with obesity may override the beneficial effects of muscle mass. 24, 25 Obesity is associated with fat infiltration (myosteatosis) to muscles, leading to poor muscle quality, strength and physical function. 24 Furthermore, because myosteatosis has been associated with insulin resistance, increased local secretion of pro-inflammatory adipokines, greater oxidative stress and mitochondrial dysfunction, 26 these metabolic dysfunctions might have attenuated the beneficial effects of muscle mass in maintaining metabolically healthy phenotype in obese subjects.
The exact mechanisms involved in the protective role of muscle mass against metabolic deterioration have not been fully elucidated.
Skeletal muscle is the primary tissue contributing to insulin-mediated glucose disposal and a previous study showed that greater muscle mass, beyond the range of sarcopenia, was associated with higher insulin sensitivity. 27 Thus, insulin sensitivity accompanied by greater muscle mass may be protective in maintaining metabolically healthy phenotype. In addition, increased resting energy expenditure and active lifestyle associated with preserved skeletal muscle mass 28 may delay progression to unhealthy phenotype. TA B L E 4 Odds ratios (ORs) with 95% confidence intervals (CI) for the development of metabolic unhealthy phenotype according to baseline appendicular skeletal muscle mass (ASM)/weight (%) quartile categories in nonobese men and women Finally, chronic inflammation linked with decreased muscle mass may promote metabolic deterioration. Low-grade inflammation and pro-inflammatory cytokines confer direct catabolic effects on muscle 32 and promote insulin resistance and metabolic deterioration.
Therefore, inflammation associated with low skeletal muscle mass may be critical for metabolic deterioration.
Our current study has several limitations. First, we did not assess nutritional intake, and information on physical activity, smoking status and alcohol consumption was self-reported, which may result in recall bias. Second, we did not take into account muscle function, which is associated with metabolic disorder, 25 and estimated skeletal muscle mass using BIA. To assess muscle mass, computed tomography, magnetic resonance imaging and dual energy X-ray absorptiom- However, our study had several strengths. First, we performed a longitudinal analysis and showed that greater skeletal muscle mass at baseline prevents future metabolic deterioration in a relatively large number of individuals among the general population.
Although previous studies showed that low skeletal muscle mass was associated with metabolically unhealthy phenotype, 10,11 those studies were cross-sectional in design and the relationship was limited to the lower, sarcopenic range of muscle mass. Second, unlike previous studies, 10, 11 we meticulously excluded individuals with abnormal thyroid function and chronic kidney disease, both of which are closely associated with metabolic disorders or a decrease in skeletal muscle mass. 17, 18 Third, in contrast to previous studies, 10, 11 our multiple logistic regression analysis adjusted for multiple metabolic risk factors that are possibly associated with metabolic health, including age, smoking, alcohol consumption, regular aerobic exercise, regular resistance exercise, diabetes, hypertension, use of lipid-lowering drugs, menopausal status, TG, HDL-C, uric acid, hsCRP, HOMA-IR, BMI and WC. We adjusted specifically for menopausal status, which independently contributes to metabolic phenotype, CVD risk and low skeletal muscle mass.
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TA B L E 5 Odds ratios (ORs) with 95% confidence intervals (CI) for the development of metabolic unhealthy phenotype according to baseline appendicular skeletal muscle mass (ASM)/weight (%) quartile categories in men and women with obesity 
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